Drugs that contain Selumetinib Sulfate

1. List of Koselugo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Apr, 2024

(1 year, 2 months from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 10, 2025
Orphan Drug Exclusivity (ODE) Apr 10, 2027

NCE-1 date: April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in